Summit Therapeutics (SMMT) Cost of Revenue (2017 - 2020)
Summit Therapeutics' (SMMT) quarterly Cost of Revenue came in at $7.9 million in Q1 2020, down 6.17% YoY from $8.4 million in Q2 2019, and up 176.64% on a QoQ basis from -$10.3 million in Q4 2019.
Summit Therapeutics (SMMT) Cost of Revenue (2017 - 2020) Analysis & Trends
Summit Therapeutics (SMMT) has 4 years of Cost of Revenue data on file, last reported at $7.9 million in Q1 2020.
- Quarterly Cost of Revenue fell 6.17% year-over-year to $7.9 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $15.2 million (down 71.83% YoY) and the FY2019 annual result came in at $33.3 million, changed N/A from the prior year.
- Cost of Revenue rose to $7.9 million in Q1 2020, from -$10.3 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $18.6 million in Q1 2018 to a low of -$10.3 million in Q4 2019.
- A 4-year average of $9.9 million and a median of $10.0 million in 2019 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2018 — Cost of Revenue soared 57.32% — and 2019, when it sank 55.6%.
- Tracing SMMT's Cost of Revenue over 4 years: stood at $10.3 million in 2017, then climbed by 26.36% to $13.0 million in 2018, then tumbled by 179.42% to -$10.3 million in 2019, then surged by 176.64% to $7.9 million in 2020.
- The last three Cost of Revenue figures came in at $7.9 million (Q1 2020), -$10.3 million (Q4 2019), and $9.7 million (Q4 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 7.92 Mn |
| Mar 31, 2020 | 7.92 Mn |
| Dec 31, 2019 | -10.34 Mn |
| Dec 31, 2019 | -10.34 Mn |
| Oct 31, 2019 | 9.68 Mn |
| Oct 31, 2019 | 9.68 Mn |
| Jul 31, 2019 | 7.97 Mn |
| Jul 31, 2019 | 7.97 Mn |
| Mar 31, 2019 | 8.44 Mn |
| Mar 31, 2019 | 8.44 Mn |
| Oct 31, 2018 | 13.02 Mn |
| Oct 31, 2018 | 13.02 Mn |
| Jul 31, 2018 | 17.95 Mn |
| Jul 31, 2018 | 17.95 Mn |
| Apr 30, 2018 | 14.67 Mn |
| Apr 30, 2018 | 14.67 Mn |
| Jan 31, 2018 | 18.59 Mn |
| Jan 31, 2018 | 18.59 Mn |
| Oct 31, 2017 | 10.30 Mn |
| Oct 31, 2017 | 10.30 Mn |